From the Food and Drug Administration.
Nightingale
S L
SL
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D004348:Drug Labeling / Q000592:standards*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D018805:Sepsis / Q000209:etiology*; D013607:Tablets / Q000592:standards; D065227:Transfusion Reaction; D014481:United States; D014486:United States Food and Drug Administration; D001084:Vidarabine Phosphate / Q000031:analogs & derivatives / Q000627:therapeutic use; D015009:Yersinia Infections; D015008:Yersinia enterocolitica
D000964:Antimetabolites, Antineoplastic; D013607:Tablets; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate